文献速递头颈部肿瘤放疗

人乳头瘤病毒相关口咽癌的降强度放疗:何人、为何、何为、何处、何时、如何、剂量几何及后续方向

De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much…and what next?
PubMed 文献 · Radiother Oncol · 2024-06-08

本文综述人乳头瘤病毒(HPV)相关口咽鳞癌降强度放疗的可行性与争议,指出HPV阳性患者因放射敏感性高而预后显著优于HPV阴性患者,降强度目标是维持治愈率并减少急慢性毒性。已发表的前瞻性研究显示降强度放疗可在合适选择患者中维持高治愈率并保留生活质量,但研究设计异质性大,如何用于真实世界实践仍存疑问。

要点

  • HPV阳性口咽癌因放射敏感性高,预后显著优于HPV阴性者,是降强度治疗的依据。
  • 前瞻性研究显示降强度放疗可在合适选择患者中维持高治愈率并保留生活质量。
  • 降强度研究设计异质性大,真实世界应用及转化研究整合仍存多重不确定性。

核心结论

  • 降强度放疗是HPV相关口咽癌的可行选择,前瞻性研究显示可在合适选择患者中维持高治愈率并保留生活质量,但研究设计异质性大,真实世界应用仍存疑问。

研究设计与样本

  • 本文为综述,围绕HPV相关口咽癌降强度放疗的若干问题展开讨论。

主要发现

  • HPV阳性口咽癌患者因放射敏感性高,预后显著优于HPV阴性患者。
  • 降强度治疗的根本目标是维持传统方法的高治愈率和生存率,同时降低治疗强度及急慢性毒性发生率。
  • 已发表的前瞻性研究显示降强度放疗可在合适选择患者中成功维持高治愈率并保留生活质量。
  • 这些研究设计异质性较大,其发现如何应用于真实世界实践仍存疑问。
  • 将转化研究整合入临床范式的潜力刚开始被认识。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 降强度放疗研究设计异质性较大。
  • 如何将研究结果应用于真实世界实践仍存疑问。
  • HPV阳性口咽癌对治疗敏感性提高的确切原因尚不确定。
  • 将转化研究整合入临床范式刚起步。
  • HPV阳性口咽癌降强度治疗仍存在多重不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The emergence of treatment de-escalation as a feasible option for patients with newly diagnosed human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma has generated considerable excitement among both providers and patients alike. Since HPV-positive oropharyngeal carcinoma has been shown to be a unique entity with distinct clinical and molecular characteristics, the rationale for customizing treatment for patients with this disease is compelling. Indeed, evidence has accumulated demonstrating that patients with HPV-positive oropharyngeal cancer have a significantly improved prognosis as a result of their exquisite radiosensitivity compared to their HPV-negative counterparts and thus might possibly be targeted with de-escalated approaches. The fundamental goal of de-escalation is to maintain the high cure and survival rates associated with traditional approaches while reducing the intensity of treatment and thus the incidence of both short- and long-term toxicity. Given the rapidly increasing incidence of this disease, particularly among younger patients who are generally healthy, the focus on quality of life seems germane. Although the exact reason for the improved sensitivity of HPV-positive oropharyngeal carcinoma to treatment is uncertain, prospective studies have now been published demonstrating that de-escalated radiation can successfully maintain the high rates of cure and preserve quality of life for appropriately selected patients with this disease. However, these studies have been fairly heterogeneous in design, and it remains questionable how to apply their findings to real-world practice. The potential of integrating translational approaches into clinical paradigms is also just starting to become recognized. Consequently, multiple uncertainties continue to exist with respect to de-escalation for HPV-positive oropharyngeal cancer, and these questions comprise the crux of this review.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chen AM. De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much…and what next? Radiother Oncol. 2024. PMID: 38857702. doi:10.1016/j.radonc.2024.110373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。